Description
CJC-1295 DAC + Ipamorelin combines a long-acting GHRH analog with a selective ghrelin receptor agonist, studied for dual-pathway GH axis activation in models where sustained GHRH receptor background and simultaneous GHSR-1a stimulation are both experimental requirements. CJC-1295 DAC maintains GHRH receptor engagement for approximately 6–8 days through its albumin-binding Drug Affinity Complex. Ipamorelin activates GHSR-1a selectively — without significant off-target ACTH or cortisol pathway activity — through a Gq-coupled calcium cascade that operates independently of GHRH receptor input. Researchers use this combination when the experimental question involves how sustained GHRH axis stimulation interacts with episodic ghrelin receptor activation, or when a long-duration observation window makes repeated dosing with the no DAC + Ipamorelin blend impractical.
Key Characteristics
- The DAC format changes the experimental design relative to the no DAC blend — sustained GHRH receptor background rather than pulsatile input means this combination is better suited for studying cumulative dual-pathway effects over days rather than pulse dynamics within a single session
- Ipamorelin’s GHSR-1a selectivity is particularly important in long-duration models — its clean receptor profile reduces the accumulation of off-target confounds that would complicate interpretation across a multi-day observation window
- Downstream IGF-1 kinetics differ substantially from the no DAC blend — the sustained GHRH receptor background produced by CJC-1295 DAC creates a different GH exposure profile for liver tissue, which directly affects the IGF-1 output pattern researchers measure as a secondary variable
- Clinical data for CJC-1295 DAC (standalone) documents IGF-1 elevations persisting 9–11 days after a single dose — adding Ipamorelin’s GHSR-1a input to this sustained background is the specific experimental condition this blend is designed to study
- Researchers needing pulsatile dual-pathway models should use the CJC-1295 no DAC + Ipamorelin blend instead — DAC and no DAC formats are not interchangeable and address fundamentally different research questions
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. The DAC component provides greater enzymatic stability than the no DAC format, but consistent cold-chain handling remains important for maintaining the integrity of both compounds in the blend. Avoid repeated freeze-thaw cycles.
FAQs
What is the CJC-1295 DAC + Ipamorelin blend used for in research?
This blend is used in GH axis research models requiring sustained dual-pathway activation — GHRH receptor engagement maintained over days by CJC-1295 DAC, combined with episodic GHSR-1a activation from Ipamorelin. Researchers use it when the experimental question involves cumulative dual-pathway GH axis dynamics rather than pulsatile release pattern analysis.
How does this blend differ from CJC-1295 no DAC + Ipamorelin?
The core difference is the observation window and signaling pattern. CJC-1295 no DAC produces a short GHRH signal that preserves pulsatile dynamics — that blend is studied for pulse architecture. CJC-1295 DAC maintains sustained GHRH receptor activation for days — this blend is studied for longer-duration cumulative GH axis responses. The two blends ask different research questions and are not interchangeable.
Why does Ipamorelin’s receptor selectivity matter more in this blend than in shorter-duration models?
In multi-day protocols, any off-target pathway activity compounds over time. Ipamorelin’s high selectivity for GHSR-1a — unlike earlier ghrelin receptor agonists that also activate ACTH and cortisol pathways — keeps the ghrelin receptor input clean across the full duration of the experiment. This matters more in a DAC-based long-observation model than in a single short-session protocol, where cumulative off-target effects are less likely to confound interpretation.
